IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Boosted by Ellevest Inc.

Ellevest Inc. raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 10.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 994 shares of the company’s stock after purchasing an additional 93 shares during the period. Ellevest Inc.’s holdings in IDEXX Laboratories were worth $435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Panagora Asset Management Inc. grew its stake in shares of IDEXX Laboratories by 50.3% in the first quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock worth $1,768,000 after acquiring an additional 1,081 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of IDEXX Laboratories by 26.8% in the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock worth $888,000 after acquiring an additional 343 shares during the last quarter. Cetera Investment Advisers grew its stake in shares of IDEXX Laboratories by 77.1% in the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock worth $2,010,000 after acquiring an additional 1,600 shares during the last quarter. Moors & Cabot Inc. lifted its position in IDEXX Laboratories by 3.0% in the first quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after purchasing an additional 52 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in IDEXX Laboratories by 15.6% in the first quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after purchasing an additional 134 shares during the period. Institutional investors and hedge funds own 86.85% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $565.56 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a 50 day simple moving average of $541.90 and a 200 day simple moving average of $491.06. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $579.68. The firm has a market capitalization of $47.00 billion, a PE ratio of 56.16, a P/E/G ratio of 3.14 and a beta of 1.25.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. BNP Paribas initiated coverage on IDEXX Laboratories in a report on Thursday, December 7th. They set an “outperform” rating and a $602.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. Finally, The Goldman Sachs Group lifted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

Check Out Our Latest Report on IDXX

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP James F. Polewaczyk sold 11,636 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $521.79, for a total transaction of $6,071,548.44. Following the sale, the executive vice president now owns 10,050 shares in the company, valued at approximately $5,243,989.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,288 shares of company stock worth $34,600,528. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.